Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats

Hazem F. Elewa, Anna Kozak, Azza B. El-Remessy, Reginald F. Frye, Maribeth H Johnson, Adviye Ergul, Susan C. Fagan

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Ischemic stroke is a leading cause of death in the United States, and diabetes mellitus is a major risk factor for stroke. Our previous work showed that type II diabetic rats [Goto-Kakizaki (GK)] have more bleeding after stroke than their normoglycemic controls (Wistar). Our aim was to evaluate the vascular protective properties of acute atorvastatin therapy after experimental ischemic stroke in diabetes and to explore the effect of stroke in GK rats compared with their normoglycemic controls. Fifty male Wistar and 40 GK rats (270-305 g) underwent 3 h of middle cerebral artery occlusion followed by reperfusion for 21 h. Animals received atorvastatin (5 mg/kg), atorvastatin (15 mg/kg), or vehicle, administered by oral gavage, one dose 5 min after reperfusion and a second dose after 12 h. At 24 h, functional outcome was measured, and brain tissue was analyzed for infarct volume, hemoglobin content, and molecular biomarkers. Plasma was collected for analysis of atorvastatin concentrations. Atorvastatin-treated groups had significantly lower bleeding rates (p = 0.0011) and infarct volume (p = 0.0007) compared with controls. There was a significant reduction in hemoglobin content and infarct volume only in the higher dose group (15 mg/kg) (p < 0.05), and these benefits were more than 4 times greater in the diabetic animals. Atorvastatin (15 mg/kg) improved neurological outcome in both Wistar and GK rats (p = 0.029) at a peak concentration of 27 to 77 ng/ml and was associated with an increase in Akt phosphorylation (p = 0.0007). We concluded that atorvastatin is a vascular protective agent after experimental ischemic stroke, especially in diabetes.

Original languageEnglish (US)
Pages (from-to)532-540
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume330
Issue number2
DOIs
StatePublished - Aug 1 2009

Fingerprint

Brain Ischemia
Hemorrhage
Stroke
Reperfusion
Blood Vessels
Hemoglobins
Protective Agents
Investigational Therapies
Middle Cerebral Artery Infarction
Atorvastatin Calcium
Cause of Death
Diabetes Mellitus
Biomarkers
Phosphorylation
Brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. / Elewa, Hazem F.; Kozak, Anna; El-Remessy, Azza B.; Frye, Reginald F.; Johnson, Maribeth H; Ergul, Adviye; Fagan, Susan C.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 330, No. 2, 01.08.2009, p. 532-540.

Research output: Contribution to journalArticle

Elewa, Hazem F. ; Kozak, Anna ; El-Remessy, Azza B. ; Frye, Reginald F. ; Johnson, Maribeth H ; Ergul, Adviye ; Fagan, Susan C. / Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 330, No. 2. pp. 532-540.
@article{be6345bdcda441ba90473bfdbe4b9d17,
title = "Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats",
abstract = "Ischemic stroke is a leading cause of death in the United States, and diabetes mellitus is a major risk factor for stroke. Our previous work showed that type II diabetic rats [Goto-Kakizaki (GK)] have more bleeding after stroke than their normoglycemic controls (Wistar). Our aim was to evaluate the vascular protective properties of acute atorvastatin therapy after experimental ischemic stroke in diabetes and to explore the effect of stroke in GK rats compared with their normoglycemic controls. Fifty male Wistar and 40 GK rats (270-305 g) underwent 3 h of middle cerebral artery occlusion followed by reperfusion for 21 h. Animals received atorvastatin (5 mg/kg), atorvastatin (15 mg/kg), or vehicle, administered by oral gavage, one dose 5 min after reperfusion and a second dose after 12 h. At 24 h, functional outcome was measured, and brain tissue was analyzed for infarct volume, hemoglobin content, and molecular biomarkers. Plasma was collected for analysis of atorvastatin concentrations. Atorvastatin-treated groups had significantly lower bleeding rates (p = 0.0011) and infarct volume (p = 0.0007) compared with controls. There was a significant reduction in hemoglobin content and infarct volume only in the higher dose group (15 mg/kg) (p < 0.05), and these benefits were more than 4 times greater in the diabetic animals. Atorvastatin (15 mg/kg) improved neurological outcome in both Wistar and GK rats (p = 0.029) at a peak concentration of 27 to 77 ng/ml and was associated with an increase in Akt phosphorylation (p = 0.0007). We concluded that atorvastatin is a vascular protective agent after experimental ischemic stroke, especially in diabetes.",
author = "Elewa, {Hazem F.} and Anna Kozak and El-Remessy, {Azza B.} and Frye, {Reginald F.} and Johnson, {Maribeth H} and Adviye Ergul and Fagan, {Susan C.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1124/jpet.108.146951",
language = "English (US)",
volume = "330",
pages = "532--540",
journal = "The Journal of pharmacology and experimental therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats

AU - Elewa, Hazem F.

AU - Kozak, Anna

AU - El-Remessy, Azza B.

AU - Frye, Reginald F.

AU - Johnson, Maribeth H

AU - Ergul, Adviye

AU - Fagan, Susan C.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Ischemic stroke is a leading cause of death in the United States, and diabetes mellitus is a major risk factor for stroke. Our previous work showed that type II diabetic rats [Goto-Kakizaki (GK)] have more bleeding after stroke than their normoglycemic controls (Wistar). Our aim was to evaluate the vascular protective properties of acute atorvastatin therapy after experimental ischemic stroke in diabetes and to explore the effect of stroke in GK rats compared with their normoglycemic controls. Fifty male Wistar and 40 GK rats (270-305 g) underwent 3 h of middle cerebral artery occlusion followed by reperfusion for 21 h. Animals received atorvastatin (5 mg/kg), atorvastatin (15 mg/kg), or vehicle, administered by oral gavage, one dose 5 min after reperfusion and a second dose after 12 h. At 24 h, functional outcome was measured, and brain tissue was analyzed for infarct volume, hemoglobin content, and molecular biomarkers. Plasma was collected for analysis of atorvastatin concentrations. Atorvastatin-treated groups had significantly lower bleeding rates (p = 0.0011) and infarct volume (p = 0.0007) compared with controls. There was a significant reduction in hemoglobin content and infarct volume only in the higher dose group (15 mg/kg) (p < 0.05), and these benefits were more than 4 times greater in the diabetic animals. Atorvastatin (15 mg/kg) improved neurological outcome in both Wistar and GK rats (p = 0.029) at a peak concentration of 27 to 77 ng/ml and was associated with an increase in Akt phosphorylation (p = 0.0007). We concluded that atorvastatin is a vascular protective agent after experimental ischemic stroke, especially in diabetes.

AB - Ischemic stroke is a leading cause of death in the United States, and diabetes mellitus is a major risk factor for stroke. Our previous work showed that type II diabetic rats [Goto-Kakizaki (GK)] have more bleeding after stroke than their normoglycemic controls (Wistar). Our aim was to evaluate the vascular protective properties of acute atorvastatin therapy after experimental ischemic stroke in diabetes and to explore the effect of stroke in GK rats compared with their normoglycemic controls. Fifty male Wistar and 40 GK rats (270-305 g) underwent 3 h of middle cerebral artery occlusion followed by reperfusion for 21 h. Animals received atorvastatin (5 mg/kg), atorvastatin (15 mg/kg), or vehicle, administered by oral gavage, one dose 5 min after reperfusion and a second dose after 12 h. At 24 h, functional outcome was measured, and brain tissue was analyzed for infarct volume, hemoglobin content, and molecular biomarkers. Plasma was collected for analysis of atorvastatin concentrations. Atorvastatin-treated groups had significantly lower bleeding rates (p = 0.0011) and infarct volume (p = 0.0007) compared with controls. There was a significant reduction in hemoglobin content and infarct volume only in the higher dose group (15 mg/kg) (p < 0.05), and these benefits were more than 4 times greater in the diabetic animals. Atorvastatin (15 mg/kg) improved neurological outcome in both Wistar and GK rats (p = 0.029) at a peak concentration of 27 to 77 ng/ml and was associated with an increase in Akt phosphorylation (p = 0.0007). We concluded that atorvastatin is a vascular protective agent after experimental ischemic stroke, especially in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=67651011803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651011803&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.146951

DO - 10.1124/jpet.108.146951

M3 - Article

C2 - 19478137

AN - SCOPUS:67651011803

VL - 330

SP - 532

EP - 540

JO - The Journal of pharmacology and experimental therapeutics

JF - The Journal of pharmacology and experimental therapeutics

SN - 0022-3565

IS - 2

ER -